By VHIO –
One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the VHIO’s Growth Factors Group, and the Cancer Research Program of Hospital del Mar Research Institute (HMRIB), Barcelona, have developed novel chimeric antigen receptor (CAR) T-cell therapy that can produce a potent antitumor response against p95HER2-expressing cells.
This novel approach consists of T cells engineered to express a CAR against p95HER2 and secrete the TECH2Me bispecific antibody that specifically recognizes tumor cells. In addition, this bispecific antibody activates immune cells within the tumor microenvironment (TME). This new therapeutic strategy has been evaluated in patient-derived models of HER2+ P95HER2-expressing solid tumors.
